Skip to main content

Gene Logic Sells GeneExpress Subscription to Japan s Takeda

NEW YORK, March 27 - Takeda has subscribed to Gene Logic's GeneExpress database and tools, Gene Logic said on Wednesday.


The multi-year deal gives the Japanese pharma the use of GeneExpress as well as broad access to Gene Logic's BioExpress and ToxExpress information and tools.


Financial terms of the deal, completed in collaboration with Amersham Biosciences KK, Gene Logic's sales and marketing partner in Japan, were not disclosed.

BioExpress includes genomic and clinical data derived from a variety of normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines. ToxExpress is a database containing
expression profiles from organs affected by toxicity and the results of rat and human cell samples treated with various compounds. Gene Logic claims ToxExpress can predict what compounds may cause liver toxicity. GeneExpress was designed to help researchers mine, analyze, index, and visualize data.


Takeda, a Japanese drug and vitamin powerhouse, has annual sales topping $7 billion.


Earlier in the month, Gene Logic sold a multi-year subscription to its GeneExpress and BioExpress data suites to Japanese pharma Daiichi.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.